
Roche signs biggest-ever obesity drug deal
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma. The Swiss pharmaceutical company will collaborate with Zealand on petrelintide, a drug based…